Emerging Antifungal Targets and Strategies
Open accessThe DOI matches its Crossref record; 152 of the 154 references it cites were found in a registry or an index.
Abstract
Despite abundant research in the field of antifungal drug discovery, fungal infections remain a significant healthcare burden. There is an emerging need for the development of novel antifungals since those currently available are limited and do not completely provide safe and secure protection. Since the current knowledge regarding the physiology of fungal cells and the infection mechanisms is greater than ever, we have the opportunity to use this for the development of novel generations of antifungals. In this review, we selected and summarized recent studies describing agents employing different antifungal mechanisms. These mechanisms include interference with fungal resistance, including impact on the efflux pumps and heat shock protein 90. Additionally, interference with virulence factors, such as biofilms and hyphae; the impact on fungal enzymes, metabolism, mitochondria, and cell wall; and antifungal vaccines are explored. The agents investigated belong to different classes of natural or synthetic molecules with significant attention given also to plant extracts. The efficacy of these antifungals has been studied mainly in vitro with some in vivo, and clinical studies are needed. Nevertheless, there is a large quantity of products employing novel antifungal mechanisms that can be further explored for the development of new generation of antifungals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It was synthesized based on ToAP2 and exhibited antifungal activity against Sporothrix globosa with good serum stability and low toxicity (81).”
From Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review (2023) · cites this paper as [81]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Cell wall of fungus, being the outermost component of the cell, facilitates the initial physical interaction between microorganisms and their environment, including the host [19].”
From Mitochondrial anchor protein Num11 is key to pathogenicity of Candida albicans by affecting mitochondrial function and cell wall masking (2025) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Resistance of Candida to azoles and echinocandins worldwide
Pristov, K. E., & Ghannoum, M. A. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.03.028 · Cited by 706 · cited 1×
“The exact mechanism of resistance is linked with the mutation of two regions of the FKS1p subunit of β-(1,3) d-glucan synthase, which subsequently leads to the substitution of serine 645 for proline, phenylalanine, and tyrosine and changes the echinocandins target site [40].”
BackgroundStone, N. R. H., Bicanic, T., Salim, R., & Hope, W. (2016) · Drugs · doi:10.1007/s40265-016-0538-7 · Cited by 537 · cited 2×
“However, due to recorded significant dose-limiting toxicity of this formulation, mainly nephrotoxicity and infusion-related reactions, less toxic formulations were developed [27].”
BackgroundAmphotericin forms an extramembranous and fungicidal sterol sponge
Anderson, T. M., Clay, M. C., Cioffi, A. G., Diaz, K. A., Hisao, G. S., Tuttle, M. D., Nieuwkoop, A. J., Comellas, G., Maryum, N., Wang, S., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1496 · Cited by 528 · cited 2×
“It is proposed that extraction of the essential cell lipid underlies the antifungal action of this compound [26].”
BackgroundCampoy, S., & Adrio, J. L. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.11.019 · Cited by 511
Emerging Threats in Antifungal-Resistant Fungal Pathogens
Sanglard, D. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2016.00011 · Cited by 416 · cited 1×
“Mechanisms of antifungal resistance include decrease of effective drug concentration, drug target alterations, and metabolic bypasses [48].”
BackgroundSpampinato, C., & Leonardi, D. (2013) · BioMed Research International · doi:10.1155/2013/204237 · Cited by 411 · cited 1×
“Additionally, point mutations in ERG3 can inactivate C5 sterol desaturase leading to alterations in the ergosterol synthetic pathway and inducing azole resistance [15].”
BackgroundCavassin, F. B., Baú-Carneiro, J. L., Vilas-Boas, R. R., & Queiroz-Telles, F. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00382-7 · Cited by 382
Lemke, A., Kiderlen, A. F., & Kayser, O. (2005) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-005-1955-9 · Cited by 305
Candida Species Biofilms’ Antifungal Resistance
Silva, S., Rodrigues, C., Araújo, D., Rodrigues, M., & Henriques, M. (2017) · Journal of Fungi · doi:10.3390/jof3010008 · Cited by 302
Contribution of Clinically Derived Mutations in ERG11 to Azole Resistance in Candida albicans
Flowers, S. A., Colón, B., Whaley, S. G., Schuler, M. A., & Rogers, P. D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03470-14 · Cited by 294 · cited 1×
“Mutations in ERG11 are frequent among azole-resistant clinical fungal strains [103].”
BackgroundDrug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium
Arastehfar, A., Gabaldón, T., Garcia-Rubio, R., Jenks, J. D., Hoenigl, M., Salzer, H. J. F., Ilkit, M., Lass-Flörl, C., & Perlin, D. S. (2020) · Antibiotics · doi:10.3390/antibiotics9120877 · Cited by 292 · cited 1×
“Fungi belonging to Candida, Aspergillus, Cryptococcus, and Pneumocystis are generally recognized as the fungal pathogens with significant rates of antifungal resistance [47].”
BackgroundHsp90 Governs Dispersion and Drug Resistance of Fungal Biofilms
Robbins, N., Uppuluri, P., Nett, J., Rajendran, R., Ramage, G., Lopez-Ribot, J. L., Andes, D., & Cowen, L. E. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002257 · Cited by 291 · cited 1×
“It is also included in drug resistance of both fungal biofilms and cells in the planktonic growth conditions [109], though targeting Hsp90 is observed as a potentially”
BackgroundDe Beule, K., & Van Gestel, J. (2001) · Drugs · doi:10.2165/00003495-200161001-00003 · Cited by 283
Welscher, Y. M. T., Napel, H. H. T., Balagué, M. M., Souza, C. M., Riezman, H., de Kruijff, B., & Breukink, E. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707821200 · Cited by 274 · cited 1×
“Natamycin is a polyene antifungal; it accomplishes its antifungal effect by specific binding to ergosterol while not increasing permeability of the cell membrane [11].”
BackgroundRoscetto, E., Contursi, P., Vollaro, A., Fusco, S., Notomista, E., & Catania, M. R. (2018) · Scientific Reports · doi:10.1038/s41598-018-35530-0 · Cited by 272
Pujol, N., Zugasti, O., Wong, D., Couillault, C., Kurz, C. L., Schulenburg, H., & Ewbank, J. J. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000105 · Cited by 255 · cited 1×
“It is known that selective pressure from fungal pathogens has impact on the invertebrate innate immune response [144].”
BackgroundBasic principles of the virulence of Cryptococcus
Zaragoza, O. (2019) · Virulence · doi:10.1080/21505594.2019.1614383 · Cited by 249 · cited 1×
“These cells are called “titan cells”, and, due to their large size, including their capsule, they obstruct the removal by the immune system [125].”
BackgroundBruni, N., Capucchio, M., Biasibetti, E., Pessione, E., Cirrincione, S., Giraudo, L., Corona, A., & Dosio, F. (2016) · Molecules · doi:10.3390/molecules21060752 · Cited by 236 · cited 1×
“As recently reviewed, the antimicrobial peptides could have a wide application in both human and veterinary medicine including as antifungals [124].”
BackgroundShaw, K. J., & Ibrahim, A. S. (2020) · Journal of Fungi · doi:10.3390/jof6040239 · Cited by 229
Efficacy of nystatin for the treatment of oral candidiasis: a systematic review and meta-analysis
Lyu, X., Zhao, C., Hua, H., & Yan, Z. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s100795 · Cited by 212 · cited 2×
“It is used in the treatment of local candidiasis in the corners of the lips; mucous membranes of the oral cavity; intestines; space between fingers, nails, anorectal area, and outer ear; and prophylaxis of candidiasis in newborns [10].”
BackgroundResistance to antifungals that target CYP51
Parker, J. E., Warrilow, A. G. S., Price, C. L., Mullins, J. G. L., Kelly, D. E., & Kelly, S. L. (2014) · Journal of Chemical Biology · doi:10.1007/s12154-014-0121-1 · Cited by 204 · cited 1×
“Azole binding to the active site of CYP51 is non-competitive and induces a depletion of the final biosynthetic product—ergosterol—while it also induces accumulation of 14-methylated sterols that inhibit fungal growth by reducing the integrity of the cell membrane [14].”
BackgroundClotrimazole as a pharmaceutical: past, present and future.
Crowley, P. D., & Gallagher, H. C. (2014) · Journal of Applied Microbiology · doi:10.1111/jam.12554 · Cited by 200 · cited 2×
“In smaller doses, it has fungistatic and in higher doses fungicidal action on Candida albicans, Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, Microsporum canis, and Malassezia furfur [17].”
BackgroundSchmidt, M., Bowers, B., Varma, A., Roh, D.-H., & Cabib, E. (2002) · Journal of Cell Science · doi:10.1242/jcs.115.2.293 · Cited by 199
Hope on the Horizon: Novel Fungal Treatments in Development
Rauseo, A. M., Coler-Reilly, A., Larson, L., & Spec, A. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa016 · Cited by 199
Alcazar-Fuoli, L., & Mellado, E. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00439 · Cited by 189 · cited 1×
“Recent reviews have suggested targeting fungal efflux pumps in order to combat drug resistance [49] as well as ergosterol biosynthesis pathway [50].”
BackgroundInhibitory Effect of Sophorolipid on Candida albicans Biofilm Formation and Hyphal Growth
Haque, F., Alfatah, M., Ganesan, K., & Bhattacharyya, M. S. (2016) · Scientific Reports · doi:10.1038/srep23575 · Cited by 189 · cited 2×
“Sophorolipids, glycolipid biosurfactants isolated from Strmerella bombicola [91], and shikonin, a red pigment isolated from Lithospermum erythrorhizon [90], also possessed anti-hyphal potential.”
BackgroundMicheli, M. D., Bille, J., Schueller, C., & Sanglard, D. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.02814.x · Cited by 182 · cited 1×
“One of the antifungal resistance mechanisms in Candida strains resistant to azole antifungals is upregulation of the ATP-binding cassette transporter genes CDR1 and CDR2 (Candida drug resistance 1 and 2) [98].”
BackgroundCurrent Antimycotics, New Prospects, and Future Approaches to Antifungal Therapy
Wall, G., & Lopez-Ribot, J. L. (2020) · Antibiotics · doi:10.3390/antibiotics9080445 · Cited by 176 · cited 1×
“Antimycotics are drugs for the treatment of fungal infections, and the most commonly used are [6]:”
BackgroundThe fungal cell wall as a target for the development of new antifungal therapies
Cortés, J. C. G., Curto, M.-Á., Carvalho, V. S. D., Pérez, P., & Ribas, J. C. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.02.008 · Cited by 170 · cited 1×
“The fungal cell wall has a different structure in relation to human cells and this unique structure is an appealing target for the development of antifungal drugs [132].”
BackgroundNovel Agents and Drug Targets to Meet the Challenges of Resistant Fungi
McCarthy, M. W., Kontoyiannis, D. P., Cornely, O. A., Perfect, J. R., & Walsh, T. J. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix130 · Cited by 169 · cited 1×
“[42] indicated that different structures of fungal cells could be targeted in order to develop novel antifungals including cell wall and cell membrane; but also metabolic pathways (glyoxylate cycle, pyrimidine biosynthesis, cytochrome P450 enzymes, iron metabolism, heme biosynthesis, and acetate metabolism), signal tr…”
BackgroundThe NDV-3A vaccine protects mice from multidrug resistant Candida auris infection
Singh, S., Uppuluri, P., Mamouei, Z., Alqarihi, A., Elhassan, H., French, S., Lockhart, S. R., Chiller, T., Edwards, J. E., & Ibrahim, A. S. (2019) · PLOS Pathogens · doi:10.1371/journal.ppat.1007460 · Cited by 162 · cited 1×
“auris strains (CAU-01, CAU-03, CAU-05, CAU-07, and CAU-09) 300 μg [85]”
The Candida albicans Biofilm Matrix: Composition, Structure and Function
Pierce, C., Vila, T., Romo, J., Montelongo-Jauregui, D., Wall, G., Ramasubramanian, A., & Lopez-Ribot, J. (2017) · Journal of Fungi · doi:10.3390/jof3010014 · Cited by 159 · cited 2×
“Biofilm resistance is also enhanced by the extracellular matrix due to its complex structure composed of proteins, carbohydrates, lipids, and extracellular DNA [116].”
BackgroundTargeting Efflux Pumps to Overcome Antifungal Drug Resistance
Holmes, A. R., Cardno, T. S., Strouse, J. J., Ivnitski-Steele, I., Keniya, M. V., Lackovic, K., Monk, B. C., Sklar, L. A., & Cannon, R. D. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0050 · Cited by 156 · cited 2×
“Recent reviews have suggested targeting fungal efflux pumps in order to combat drug resistance [49] as well as ergosterol biosynthesis pathway [50].”
BackgroundReview of the Novel Investigational Antifungal Olorofim
Wiederhold, N. P. (2020) · Journal of Fungi · doi:10.3390/jof6030122 · Cited by 155
Adverse effects of voriconazole: Over a decade of use
Levine, M. T., & Chandrasekar, P. H. (2016) · Clinical Transplantation · doi:10.1111/ctr.12834 · Cited by 153 · cited 1×
“Additionally, the most concerning side effect of voriconazole use is the associated increased risk of cutaneous malignancies, primarily squamous cell carcinoma [35].”
BackgroundAn Overview of Topical Antifungal Therapy in Dermatomycoses: A North American Perspective
Gupta, A. K., Einarson, T. R., Summerbell, R. C., & Shear, N. H. (1998) · Drugs · doi:10.2165/00003495-199855050-00004 · Cited by 152
Amphotericin B lipid preparations: what are the differences?
Adler‐Moore, J., & Proffitt, R. T. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01979.x · Cited by 149 · cited 2×
“Liposomal formulation has less toxicity compared to other lipid formulations, and can be safely and repeatedly applied at high concentrations for treating infections that are challenging to cure, such as fusariosis and zygomycosis [28].”
BackgroundThe Interface between Fungal Biofilms and Innate Immunity
Kernien, J. F., Snarr, B. D., Sheppard, D. C., & Nett, J. E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01968 · Cited by 142 · cited 1×
“By forming these structures fungal pathogens are able to escape being killed by immune cells, such as neutrophils and monocytes, making the eradication of biofilms a significant challenge [114].”
BackgroundVaccines for human fungal diseases: close but still a long way to go
Oliveira, L. V. N., Wang, R., Specht, C. A., & Levitz, S. M. (2021) · npj Vaccines · doi:10.1038/s41541-021-00294-8 · Cited by 135 · cited 1×
“killed fungi, crude extracts, recombinant subunit formulations, as well as vaccines with nucleic acid as recently reviewed [142].”
MethodLv, Q.-Z., Yan, L., & Jiang, Y.-Y. (2016) · Virulence · doi:10.1080/21505594.2016.1188236 · Cited by 133 · cited 1×
“The range of drugs targeting ergosterol biosynthesis present on the pharmaceutical market include azoles targeting lanosterol 14-α demethylase; polyenes drugs that disrupt the ergosterols distributed on the membrane; and allylamines that are squalene synthase (Erg1p) inhibitors [102].”
BackgroundChakrabarti, A., & Sood, P. (2021) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001318 · Cited by 133 · cited 1×
“Likewise, multidrug-resistant yeast Candida auris some time ago emerged worldwide and became a significant threat due to its ability to rapidly develop resistance [45].”
BackgroundGao, M., Wang, H., & Zhu, L. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000453134 · Cited by 131 · cited 1×
“Further studies reports concerning anti-hyphal potential indicated that quercetin is more effective in concentration up to 200 μg/mL [121] and 64 μg/mL [122], while concentration of 75 μg/mL has induced only slight inhibition [56].”
BackgroundIbrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor
Jallow, S., & Govender, N. P. (2021) · Journal of Fungi · doi:10.3390/jof7030163 · Cited by 129
Prasath, K. G., Tharani, H., Kumar, M. S., & Pandian, S. K. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00864 · Cited by 127
Structural basis for species-selective targeting of Hsp90 in a pathogenic fungus
Whitesell, L., Robbins, N., Huang, D. S., McLellan, C. A., Shekhar-Guturja, T., LeBlanc, E. V., Nation, C. S., Hui, R., Hutchinson, A., Collins, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08248-w · Cited by 124
The Future of Antifungal Drug Therapy: Novel Compounds and Targets
Mota Fernandes, C., Dasilva, D., Haranahalli, K., McCarthy, J. B., Mallamo, J., Ojima, I., & Del Poeta, M. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01719-20 · Cited by 124 · cited 1×
“However, since limited percentage of compounds that are currently undergoing clinical studies will be finally approved for further human use, it is necessary that additional antifungal compounds are detected and explored at this moment and in the future [41].”
BackgroundDetailed Mechanism of Squalene Epoxidase Inhibition by Terbinafine
Nowosielski, M., Hoffmann, M., Wyrwicz, L. S., Stepniak, P., Plewczynski, D. M., Lazniewski, M., Ginalski, K., & Rychlewski, L. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci100403b · Cited by 123 · cited 1×
“Squalene epoxidase is an essential flavin adenine dinucleotide-dependent enzyme of ergosterol and cholesterol biosynthetic pathways with a role in catalyzing the stereospecific epoxidation of squalene to 2,3-(S)-oxidosqualene [20].”
BackgroundThe Rise and Fall of Oral Ketoconazole
Gupta, A. K., & Lyons, D. C. A. (2015) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475415574970 · Cited by 120 · cited 4×
“The active substance and auxiliary ingredients in the cream sometimes cause a local allergic reaction (contact dermatitis) [19].”
BackgroundInfluentialUsnic acid inhibits biofilm formation and virulent morphological traits of Candida albicans
Nithyanand, P., Shafreen, R. B., Muthamil, S., & Pandian, S. K. (2015) · Microbiological Research · doi:10.1016/j.micres.2015.06.009 · Cited by 119
Pharmacology of the allylamines
Birnbaum, J. E. (1990) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(90)70288-s · Cited by 119 · cited 1×
“While naftifine possesses only topical activity, its analog terbinafine is active both topically and orally [21].”
BackgroundPolyene antibiotic that inhibits membrane transport proteins
te Welscher, Y. M., van Leeuwen, M. R., de Kruijff, B., Dijksterhuis, J., & Breukink, E. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203375109 · Cited by 114 · cited 1×
“Natamycin induces ergosterol-specific and reversible inhibition of membrane transport proteins, and by inhibiting membrane transport it eventually inhibits fungal growth [12].”
BackgroundCurto, M.-Á., Butassi, E., Ribas, J. C., Svetaz, L. A., & Cortés, J. C. G. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153556 · Cited by 109 · cited 2×
“β(1,3)-D-glucan synthases inhibitors described belong to cyclic lipopeptides, glycolipids and acidic terpenoids [133].”
BackgroundAdvances in Topical and Systemic Antifungals
Zhang, A. Y., Camp, W. L., & Elewski, B. E. (2007) · Dermatologic Clinics · doi:10.1016/j.det.2007.01.002 · Cited by 108 · cited 1×
“Amines are mainly used for the topical treatment of fungal infections [8].”
BackgroundEchinocandins: structural diversity, biosynthesis, and development of antimycotics
Hüttel, W. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-020-11022-y · Cited by 105 · cited 1×
“Their mechanism of activity is based on the inhibition of 1,3-β-D-glucan synthase, which subsequently interferes the synthesis of β-(1,3) d-glucan, an essential cell wall polysaccharide [39].”
BackgroundIvanov, M., Kannan, A., Stojković, D. S., Glamočlija, J., Calhelha, R. C., Ferreira, I. C. F. R., Sanglard, D., & Sokóvić, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020483 · Cited by 104
Self-citationLipid Biosynthesis as an Antifungal Target
Pan, J., Hu, C., & Yu, J.-H. (2018) · Journal of Fungi · doi:10.3390/jof4020050 · Cited by 98
Rosmarinic acid–Modes of antimicrobial and antibiofilm activities of a common plant polyphenol
Ivanov, M., Kostić, M., Stojković, D., & Soković, M. (2022) · South African Journal of Botany · doi:10.1016/j.sajb.2021.11.050 · Cited by 98 · cited 2×
“1 mg/mL) mitochondrial activity declined for more than 50% [89].”
BackgroundSelf-citationFungal cell wall: An underexploited target for antifungal therapies
Ibe, C., & Munro, C. A. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1009470 · Cited by 96 · cited 1×
“Those enzymes are included in cell wall synthesis, thus are attractive antifungal targets since inhibiting their synthesis and localization to the cell wall could stroke on virulence and cell wall biosynthesis significantly [136].”
BackgroundPiérard, G., Arrese, J., & Piérard-Franchimont, C. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.2.287 · Cited by 92
Bae, M., Kim, H., Moon, K., Nam, S., Shin, J., Oh, K., & Oh, D. (2015) · Organic Letters · doi:10.1021/ol5037248 · Cited by 91
Mann, P. A., McLellan, C. A., Koseoglu, S., Si, Q., Kuzmin, E., Flattery, A., Harris, G., Sher, X., Murgolo, N., Wang, H., et al. (2015) · ACS Infectious Diseases · doi:10.1021/id5000212 · Cited by 88
Janeczko, M., Masłyk, M., Kubiński, K., & Golczyk, H. (2017) · Yeast · doi:10.1002/yea.3230 · Cited by 88 · cited 1×
“Likewise, another natural product, emodin (1,3,8-trihydroxy-6-methyl anthraquinone), isolated from Rheum palmatum rhizomes [74], was shown to reduce fungal hyphal growth in C.”
BackgroundMiconazole: a historical perspective
Fothergill, A. W. (2006) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.4.2.171 · Cited by 87 · cited 2×
“When using miconazole in the form of a cream, sporadic cases of maceration, allergic dermatitis, irritation, and redness of the skin have been described [18].”
BackgroundMethodShao, J., Zhang, M., Wang, T., Li, Y., & Wang, C. (2016) · Pharmaceutical Biology · doi:10.3109/13880209.2015.1091483 · Cited by 86
Singh, B. N., Upreti, D. K., Singh, B. R., Pandey, G., Verma, S., Roy, S., Naqvi, A. H., & Rawat, A. K. S. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03599-14 · Cited by 84 · cited 1×
“Further studies reports concerning anti-hyphal potential indicated that quercetin is more effective in concentration up to 200 μg/mL [121] and 64 μg/mL [122], while concentration of 75 μg/mL has induced only slight inhibition [56].”
BackgroundManoharan, R. K., Lee, J.-H., & Lee, J. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.01476 · Cited by 83 · cited 1×
“01% camphor with reduced expression of ECE1 (extent of cell elongation), a hypha-specific gene [123].”
BackgroundEffect of Shikonin Against Candida albicans Biofilms
Yan, Y., Tan, F., Hao, M., Wang, H., & Cao, Y. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01085 · Cited by 81
Anti-Biofilm Activity of Cannabidiol against Candida albicans
Feldman, M., Sionov, R. V., Mechoulam, R., & Steinberg, D. (2021) · Microorganisms · doi:10.3390/microorganisms9020441 · Cited by 80
Ivanov, M., Kannan, A., Stojković, D. S., Glamočlija, J., Calhelha, R. C., Ferreira, I. C. F. R., Sanglard, D., & Sokóvić, M. (2020) · Pharmaceuticals · doi:10.3390/ph14010027 · Cited by 79 · cited 11×
“Mutations in ERG11 are frequent among azole-resistant clinical fungal strains [103].”
BackgroundInfluentialSelf-citationThe Elusive Anti-Candida Vaccine: Lessons From the Past and Opportunities for the Future
Tso, G. H. W., Reales-Calderon, J. A., & Pavelka, N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00897 · Cited by 78 · cited 1×
“There are different challenges in this area of research including fungal extensive variation and plasticity, the presence of preestablished immunological tolerance as well as the challenges in advancing protective memory responses in patients strugling with impaired adaptive immunity [141].”
BackgroundNikkomycin Z—Ready to Meet the Promise?
Larwood, D. J. (2020) · Journal of Fungi · doi:10.3390/jof6040261 · Cited by 78 · cited 1×
“For example, Nikkomycin Z inhibits formation of the chitin structure, process essential for fungi, but not mammals [137].”
BackgroundBhatia, A., Kanish, B., Badyal, D. K., Kate, P., & Choudhary, S. (2019) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_578_17 · Cited by 77 · cited 1×
“Therapy lasts shorter than with other antifungal drugs—when terbinafine is administered in the form of a cream, the withdrawal of clinical symptoms usually occurs within a few days, and therapy lasts up to two weeks [36].”
BackgroundYamashita, K., Miyazaki, T., Fukuda, Y., Mitsuyama, J., Saijo, T., Shimamura, S., Yamamoto, K., Imamura, Y., Izumikawa, K., Yanagihara, K., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00374-19 · Cited by 77 · cited 2×
“T-2307 is a selective inhibitor and has little effect on bovine respiratory chain complexes [60].”
BackgroundĆirić, A., Petrović, J. D., Glamočlija, J., Smiljkovic, M. S., Nikolić, M., Stojković, D. S., & Sokóvić, M. (2018) · South African Journal of Botany · doi:10.1016/j.sajb.2018.09.010 · Cited by 75 · cited 1×
“Different products, including the ones from natural sources, have been studied so far due to their antibiofilm activities [119,120]; however, the search for efficient antibiofilm agents continues until today.”
BackgroundSelf-citationTrends in Azole Resistance in Aspergillus fumigatus, the Netherlands, 1994–2016
Buil, J. B., Snelders, E., Denardi, L. B., Melchers, W. J. G., & Verweij, P. E. (2019) · Emerging Infectious Diseases · doi:10.3201/eid2501.171925 · Cited by 75
Janbon, G., Quintin, J., Lanternier, F., & d’Enfert, C. (2019) · Microbes and Infection · doi:10.1016/j.micinf.2019.06.011 · Cited by 74
Mayer, F. L., & Kronstad, J. W. (2017) · mBio · doi:10.1128/mbio.01537-17 · Cited by 73 · cited 2×
“Mayer and Kronstad [126] demonstrated inhibitory effect of Bacillus safensis, which potently blocked several key C. neoformans virulence factors, such as reduction in overall cell size and completely block fungal capsule formation. α-Cyperone, from the rhizome of Cyperus rotundus, could be used for the interference wi…”
BackgroundBerberine reverses multidrug resistance in Candida albicans by hijacking the drug efflux pump Mdr1p
Tong, Y., Zhang, J., Sun, N., Wang, X.-M., Wei, Q., Zhang, Y., Huang, R., Pu, Y., Dai, H., Ren, B., et al. (2021) · Science Bulletin · doi:10.1016/j.scib.2020.12.035 · Cited by 70
Mitchell, T. G. (2012) · Emerging infectious diseases · doi:10.3201/eid1808.120521 · Cited by 69 · cited 2×
“Fungi causing disease in humans morphologically can be yeasts, molds, and biphasic (dimorphic) fungi [1].”
BackgroundIn Vitro Antibiofilm Activity of Eucarobustol E against Candida albicans
Liu, R.-H., Shang, Z.-C., Li, T.-X., Yang, M.-H., & Kong, L.-Y. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02707-16 · Cited by 68 · cited 1×
“to-hypha transition and reduces the cellular surface hydrophobicity of the biofilm cells [75].”
BackgroundExploiting mitochondria as targets for the development of new antifungals
Li, D., & Calderone, R. (2017) · Virulence · doi:10.1080/21505594.2016.1188235 · Cited by 67
Sharma, A., & Taniguchi, J. (2017) · The Ocular Surface · doi:10.1016/j.jtos.2017.06.001 · Cited by 67 · cited 1×
“Side effects include chest pain and dyspnea [13].”
BackgroundAntifungal activity of magnoflorine against Candida strains
Kim, J., Bao, T. H. Q., Shin, Y., & Kim, K.-Y. (2018) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-018-2549-x · Cited by 67 · cited 1×
“albicans virulence, also displaying antibiofilm potential [78].”
Experimental mouse models of disseminated Candida auris infection
Xin, H., Mohiuddin, F., Tran, J., Adams, A., & Eberle, K. (2019) · mSphere · doi:10.1128/msphere.00339-19 · Cited by 67 · cited 1×
“auris [145], while mouse are among the most commonly used fungal infection models of mammals [146].”
BackgroundWang, Y., Wang, K., Masso-Silva, J. A., Rivera, A., & Xue, C. (2019) · mBio · doi:10.1128/mbio.02145-19 · Cited by 67 · cited 1×
“fumigatus R21 5 × 107 heat-killed fungal cells [76]”
In silico Design of a Multivalent Vaccine Against Candida albicans
Tarang, S., Kesherwani, V., LaTendresse, B., Lindgren, L., Rocha-Sanchez, S. M., & Weston, M. D. (2020) · Scientific Reports · doi:10.1038/s41598-020-57906-x · Cited by 67 · cited 1×
“mvPCs multivalent nature by recognizing multiple-epitopes could provide enhanced protection against complex Candida antigens [83].”
BackgroundAbirami, G., Alexpandi, R., Durgadevi, R., Kannappan, A., & Veera Ravi, A. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.561298 · Cited by 67 · cited 1×
“albicans hyphal growth, biofilm formation, phospholipase and exopolysaccharide production [82].”
BackgroundChemical inhibitors of Candida albicans hyphal morphogenesis target endocytosis
Bar-Yosef, H., Gonzalez, N. V., Ben‐Aroya, S., Kron, S. J., & Kornitzer, D. (2017) · Scientific Reports · doi:10.1038/s41598-017-05741-y · Cited by 64 · cited 1×
“Hyphal form is serving as the scaffold for the biofilms and is linked with the microorganisms ability to induce infections [118].”
BackgroundHu, S., Zhu, F., Jiang, W., Wang, Y., Quan, Y., Zhang, G., Gu, F., & Yang, Y. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.658329 · Cited by 64 · cited 1×
“3% are resistant to amphotericin B and voriconazole, respectively [46].”
Backgroundde Aguiar, F. L. L., Santos, N. C., Cavalcante, C. S. D. P., Andreu, D., Rádis‐Baptista, G., & Gonçalves, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218339 · Cited by 64
Fungal Biofilms: In Vivo Models for Discovery of Anti-Biofilm Drugs
Nett, J. E., & R. Andes, D. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.mb-0008-2014 · Cited by 60 · cited 1×
“These in vivo models can be used also for the examination of antifungals targeting biofilms [147].”
BackgroundInteresting antifungal drug targets in the central metabolism of Candida albicans
Wijnants, S., Vreys, J., & Dijck, P. V. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.10.003 · Cited by 54 · cited 1×
“These pathways include N-acetylglucosamine metabolism, trehalose metabolism, lipid biosynthesis, and other essential processes in fungal cells [128,129].”
BackgroundMorphology Changes in Human Fungal Pathogens upon Interaction with the Host
Li, Z., & Nielsen, K. (2017) · Journal of Fungi · doi:10.3390/jof3040066 · Cited by 53 · cited 1×
“The cAMP-PKA (cyclic adenosine monophosphate-protein kinase A) pathway and molecular chaperone Hsp90 pathways are used to control these morphological changes in many of the human pathogenic fungi [117].”
BackgroundMolecular targets for antifungals in amino acid and protein biosynthetic pathways
Kuplińska, A., & Rząd, K. (2021) · Amino Acids · doi:10.1007/s00726-021-03007-6 · Cited by 53 · cited 1×
“glabrata, but has no effect against Aspergillus species [51].”
BackgroundWurster, S., Bandi, A., Beyda, N. D., Albert, N. D., Raman, N. M., Raad, I. I., & Kontoyiannis, D. P. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz100 · Cited by 52
A curcumin-sophorolipid nanocomplex inhibits Candida albicans filamentation and biofilm development
Rajasekar, V., Darne, P. A., Prabhune, A. A., Kao, R. Y. T., Solomon, A. P., Ramage, G., Samaranayake, L. P., & Neelakantan, P. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.111617 · Cited by 52 · cited 8×
“Mutations in ERG11 are frequent among azole-resistant clinical fungal strains [103].”
BackgroundInfluentialCabib, E., & Schmidt, M. (2003) · FEMS Microbiology Letters · doi:10.1016/s0378-1097(03)00477-4 · Cited by 49 · cited 1×
“Chitin synthase enzymes are synthesized in the cytoplasm and then transported to the cell membrane for chitin synthesis [134,135].”
BackgroundXing, Y., Chen, L., Feng, Y., Zhou, Y., Zhai, Y., & Lü, J. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2913-8 · Cited by 49 · cited 2×
“has been narrowed due to the recorded high frequency of adverse effects including neurotoxicity, visual toxicity, and hepatotoxicity [34].”
BackgroundPosaconazole: An Update of Its Clinical Use
Leung, S., Poulakos, M. N., & Machin, J. D. (2015) · Pharmacy · doi:10.3390/pharmacy3040210 · Cited by 47
Yong, J., Zu, R., Huang, X., Ge, Y., & Li, Y. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01498 · Cited by 47
Caenorhabditis elegans as a model animal for investigating fungal pathogenesis
Madende, M., Albertyn, J., Sebolai, O. M., & Pohl, C. H. (2019) · Medical Microbiology and Immunology · doi:10.1007/s00430-019-00635-4 · Cited by 45 · cited 1×
“On the other hand, the disadvantages are inability to grow at 37 ◦C and absence of an adaptive immune response [143].”
BackgroundModerate levels of 5-fluorocytosine cause the emergence of high frequency resistance in cryptococci
Chang, Y. C., Lamichhane, A. K., Cai, H., Walter, P. J., Bennett, J. E., & Kwon-Chung, K. J. (2021) · Nature Communications · doi:10.1038/s41467-021-23745-1 · Cited by 44 · cited 1×
“It is used in combination with amphotericin B, the combination is the gold standard for induction therapy in cryptococcosis [23].”
MethodMontoya, M. C., Beattie, S., Alden, K. M., & Krysan, D. J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02331-19 · Cited by 42
Wong, T. Y., Loo, Y. S., Veettil, S. K., Wong, P. S., Gopinath, D., Ching, S. M., & Menon, R. K. (2020) · Scientific Reports · doi:10.1038/s41598-020-71571-0 · Cited by 42 · cited 2×
“Its efficient against range of fungi, including those resistant to azoles and amphotericin B, but lacks activity against yeasts and the Mucorales [150].”
BackgroundShukla, M., & Rohatgi, S. (2020) · Infection and Immunity · doi:10.1128/iai.00312-20 · Cited by 41 · cited 1×
“This vaccine induces both humoral and cellular immunity, and it provides higher titers of Sap2-induced antibodies that are useful for combating systemic candidiasis [88].”
BackgroundBiatriosporin D displays anti-virulence activity through decreasing the intracellular cAMP levels
Zhang, M., Chang, W., Shi, H., Zhou, Y., Zheng, S., Li, Y., Li, L., & Lou, H. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.03.004 · Cited by 40 · cited 1×
“Exploring its further anti-hyphal mechanisms revealed that Biatriosporin D regulates the Ras1-cAMP-Efg1 pathway in order to inhibit hyphal formation [64].”
BackgroundStojković, D. S., Días, M. I., Drakulić, D., Barros, L., Stevanović, M. J., Ferreira, I. C. F. R., & Sokóvić, M. (2020) · Pharmaceuticals · doi:10.3390/ph13040078 · Cited by 40 · cited 1×
“Likewise, extract obtained from Ononis spinosa displayed antibiofilm potential towards three Candida strains, while its contributing antifungal mechanism was interference with membrane integrity [86].”
BackgroundSelf-citationMcGinnis, M. R., & Tyring, S. K. (1996) · Europe PMC (PubMed Central) · Cited by 40
Han, X., Zhu, X., Hong, Z., Wei, L., Ren, Y., Wan, F., Zhu, S., Peng, H., Guo, L., Rao, L., et al. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00763 · Cited by 39 · cited 1×
“The assays studying enzyme inhibition highlighted promising activity of these compounds with IC50 < 10 μM [87].”
BackgroundZhang, T., & Chen, W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091858 · Cited by 37 · cited 1×
“albicans by employing different mechanisms, including the accumulation of reactive oxygen species and collapse of mitochondrial membrane potential [68].”
BackgroundJothi, R., Sangavi, R., Kumar, P., Pandian, S. K., & Gowrishankar, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-00485-2 · Cited by 37 · cited 1×
“The qPCR data indicated that catechol application induces significant down-regulation of RAS1, HWP1, and ALS3, genes linked with the fungal pathogenesis [69].”
BackgroundDioscin Inhibits Virulence Factors ofCandida albicans
Yang, L., Liu, X., Zhong, L., Sui, Y., Quan, G., Huang, Y., Wang, F., & Ma, T. (2018) · BioMed Research International · doi:10.1155/2018/4651726 · Cited by 35 · cited 1×
“Likewise, dioscin has also displayed wide pallet of antifungal mechanisms including impairment of biofilm formation and development, morphological transition, adhesion, and extracellular secreted phospholipase [72].”
BackgroundEffects of Hsp90 Inhibitor Ganetespib on Inhibition of Azole-Resistant Candida albicans
Yuan, R., Tu, J., Sheng, C., Chen, X., & Liu, N. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.680382 · Cited by 35 · cited 2×
“This molecule also reduces cell efflux and downregulates expression of azole resistance linked genes, CDR1, CDR2, ERG11, and MDR1, when combined with fluconazole [111].”
BackgroundPhotodynamic Therapy Is Effective Against Candida auris Biofilms
Bapat, P. S., & Nobile, C. J. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.713092 · Cited by 35
Li, Y., Shan, M., Zhu, Y., Yao, H., Li, H., Gu, B., & Zhu, Z. (2020) · PLOS ONE · doi:10.1371/journal.pone.0243066 · Cited by 35 · cited 1×
“Fungicidal activity of kalopanaxsaponin A is also based on the interference with the permeability of the cell membrane [77].”
BackgroundJahanshiri, Z., Shams‐Ghahfarokhi, M., Asghari-Paskiabi, F., Saghiri, R., & Razzaghi‐Abyaneh, M. (2017) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-017-2214-9 · Cited by 34
Ivanov, M., Gašić, U. M., Stojković, D. S., Kostić, M., Mišić, D. M., & Sokóvić, M. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/9961089 · Cited by 32
Self-citationYang, L., Guo, G., Tian, Z., Zhou, L., Zhu, L., Peng, J., Sun, C., & Huang, M. (2021) · Journal of Proteomics · doi:10.1016/j.jprot.2021.104385 · Cited by 32 · cited 1×
“albicans metabolic pathways, including those related to oxidative phosphorylation, RNA degradation, propanoate metabolism, and fatty acid metabolism [53].”
BackgroundTripathi, S., Feng, Q. F., Liu, L., Levin, D. E., Roy, K. K., Doerksen, R. J., Baerson, S. R., Shi, X., Pan, X., Xu, W., et al. (2020) · mSphere · doi:10.1128/msphere.00818-19 · Cited by 29 · cited 1×
“Sesquiterpene quinone, puupehenone, enhances the effect of caspofungin by disrupting Hsp90 activity and cell wall integrity in fungal pathogens [112].”
BackgroundRevealing the astragalin mode of anticandidal action
Ivanov, M., Kannan, A., Stojković, D. S., Glamočlija, J., Grdadolnik, S. G., Sanglard, D., & Sokóvić, M. (2020) · EXCLI journal · doi:10.17179/excli2020-2987 · Cited by 29 · cited 9×
“Upregulations of CDR1/CDR2 and MDR1 are achieved through point mutations in TAC1 and MRR1 transcription factors.”
BackgroundInfluentialSelf-citationEbrahimi-Shaghaghi, F., Noormohammadi, Z., Atyabi, S.-M., & Razzaghi‐Abyaneh, M. (2021) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2021.108772 · Cited by 29 · cited 1×
“Other studies targeted ergosterol biosynthesis by applying tormentic acid [105], benzodioxane derivatives [106], honokiol and magnolol [107], and cold atmospheric plasma [108].”
BackgroundOverview of basic medical mycology
Mitchell, T. G. (2000) · Otolaryngologic Clinics of North America · doi:10.1016/s0030-6665(00)80003-1 · Cited by 28 · cited 1×
“They are most often caused by fungi from the genera Aspergillus and Candida [1,3,4].”
BackgroundReview on fungal enzyme inhibitors – potential drug targets to manage human fungal infections
Ramakrishnan, J., Rathore, S. S., & Raman, T. (2016) · RSC Advances · doi:10.1039/c6ra01577h · Cited by 28
Ansari, M. A., Fatima, Z., Ahmad, K., & Hameed, S. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.064 · Cited by 28 · cited 1×
“[81] evaluated inhibition of glyoxylate cycle by vanillin and monoterpenoid perillyl alcohol against C.”
MethodDevelopment of Thiazolidinones as Fungal Carbonic Anhydrase Inhibitors
Güzel-Akdemir, Ö., Carradori, S., Grande, R., Demir-Yazıcı, K., Angeli, A., Supuran, C. T., & Akdemir, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082960 · Cited by 28 · cited 1×
“1–10 μM against the Candida glabrata enzyme) [92].”
BackgroundGe, Z., Ji, Q., Chen, C., Liao, Q. L., Wu, H., Liu, X., Huang, Y., Yuan, L., & Liao, F. (2015) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2015.1016511 · Cited by 26 · cited 1×
“[139] demonstrated that the 3-substituted amino-4-hydroxycoumarin derivatives could reduce chitin level.”
BackgroundAnticapsular and Antifungal Activity of α-Cyperone
Horn, C., & Vediyappan, G. (2021) · Antibiotics · doi:10.3390/antibiotics10010051 · Cited by 25
Szerencsés, B., Gácser, A., Endré, G., Domonkos, I., Tiricz, H., Vágvölgyi, C., Szolomájer, J., Howan, D. H. O., Tóth, G. K., Pfeiffer, I., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073666 · Cited by 25 · cited 1×
“Other peptide derivatives, cysteine-rich (NCR) peptides NCR335 and NCR169 derivatives, could reduce both biofilm formation and hyphal development of Candida strains examined [84].”
BackgroundHost defence peptides identified in human apolipoprotein B as promising antifungal agents
Dell’Olmo, E., Gaglione, R., Cesaro, A., Cafaro, V., Teertstra, W. R., de Cock, H., Notomista, E., Haagsman, H. P., Veldhuizen, E. J. A., & Arciello, A. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11114-3 · Cited by 24
Zheng, S., Chang, W., Zhang, M., Shi, H., & Lou, H. (2018) · Scientific Reports · doi:10.1038/s41598-017-18717-9 · Cited by 23
Targeting Unconventional Pathways in Pursuit of Novel Antifungals
Nguyen, S. A., Truong, J. Q., & Bruning, J. B. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.621366 · Cited by 23 · cited 1×
“Some unconventional pathways were also recently proposed as possible targets for the antifungal development: enolase, a part of the enolase-plasminogen complex, along with enzymes involved in the mannitol biosynthesis and purine nucleotide biosynthesis [43].”
BackgroundAn, Y., Liu, W., Xie, H., Fan, H., Han, J., & Sun, B. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113950 · Cited by 22 · cited 1×
“Other studies targeted ergosterol biosynthesis by applying tormentic acid [105], benzodioxane derivatives [106], honokiol and magnolol [107], and cold atmospheric plasma [108].”
BackgroundVaccine-Induced Protection in Two Murine Models of Invasive Pulmonary Aspergillosis
Rayens, E. A., Rabacal, W., Kang, S., Celia-Sanchez, B. N., Momany, M., & Norris, K. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670578 · Cited by 21 · cited 2×
“KEX1 and associated levels of protection reported were 75–100% [52].”
BackgroundHonokiol and Magnolol: Insights into Their Antidermatophytic Effects
Trifan, A., Bostănaru, A.-C., Luca, S. V., Temml, V., Akram, M., Herdlinger, S., Kulinowski, Ł., Skalicka‐Woźniak, K., Granica, S., Czerwińska, M. E., et al. (2021) · Plants · doi:10.3390/plants10112522 · Cited by 20 · cited 1×
“Other studies targeted ergosterol biosynthesis by applying tormentic acid [105], benzodioxane derivatives [106], honokiol and magnolol [107], and cold atmospheric plasma [108].”
BackgroundCurrent concepts in systemic and topical therapy for superficial mycoses
Millikan, L. E. (2010) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2009.12.016 · Cited by 19 · cited 1×
“The most common antifungal drugs for topical application from the azole class [7] include derivatives of imidazole (clotrimazole, bifonazole, econazole, miconazole, isoconazole, tioconazole, butoconazole, and sulconazole) and derivatives of 1,2,4 –triazole (terconazole) (Figure 2).”
BackgroundFeucht, C. L., & Patel, D. R. (2011) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2010.10.005 · Cited by 19 · cited 2×
“Antimycotics/antifungals are drugs used in the treatment of fungal infections; however, their number is limited and is significantly lower compared to drugs used to treat bacterial infections [5].”
BackgroundBvumbi, C. W., Fru, G., Stevens, M. Y., Mombeshora, M., & Mukanganyama, S. (2021) · The Scientific World JOURNAL · doi:10.1155/2021/8856147 · Cited by 19 · cited 1×
“Other studies targeted ergosterol biosynthesis by applying tormentic acid [105], benzodioxane derivatives [106], honokiol and magnolol [107], and cold atmospheric plasma [108].”
BackgroundSaibabu, V., Fatima, Z., Ahmad, K., Luqman, A. K., & Saif, H. (2020) · Current Medical Mycology · doi:10.18502/cmm.6.1.2501 · Cited by 18
In Vitro Anti-Candida Activity and Action Mode of Benzoxazole Derivatives
Staniszewska, M., Kuryk, Ł., Gryciuk, A., Kawalec, J., Rogalska, M., Baran, J., Łukowska‐Chojnacka, E., & Kowalkowska, A. (2021) · Molecules · doi:10.3390/molecules26165008 · Cited by 18
Smiljkovic, M. S., Kostić, M., Stojković, D. S., Glamočlija, J., & Sokóvić, M. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180629133218 · Cited by 17 · cited 1×
“Different products, including the ones from natural sources, have been studied so far due to their antibiofilm activities [119,120]; however, the search for efficient antibiofilm agents continues until today.”
BackgroundSelf-citationRepurposing the thrombopoietin receptor agonist eltrombopag as an anticryptococcal agent
Ko, H.-T., Hsu, L.-H., Yang, S., & Chen, Y. (2019) · Medical Mycology · doi:10.1093/mmy/myz077 · Cited by 17 · cited 1×
“Its mechanisms of action include the alteration of genes involved in calcineurin pathway, lipid biosynthesis, membrane component, and transporter genes [73].”
BackgroundFolly, M. L. D. C., Ferreira, G. F., Salvador, M. R., Sathler, A. A., Silva, G., Santos, J. C. B., dos Santos, J. R. A., Neto, W. R. N., Rodrigues, J. F. S., Fernandes, E. S., et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.03114 · Cited by 17 · cited 2×
“neoformans (ATCC 24067, ATCC 28957, ATCC 62066, and ATCC H99) 1–16 mg/L [95]”
BackgroundSynergistic effects of vorinostat (SAHA) and azoles against Aspergillus species and their biofilms
Tu, B., Yin, G., & Li, H. (2020) · BMC Microbiology · doi:10.1186/s12866-020-1718-x · Cited by 17 · cited 1×
“Likewise, the synergistic effects of vorinostat with azoles against Aspergillus species is based on the Hsp90 suppression [113].”
BackgroundTerbinafine-induced neutropenia.
Shapiro, M., Lj, L., & Miller, J. T. (1999) · PubMed · Cited by 16
Antifungal Activity of ToAP2D Peptide Against Sporothrix globosa
Yan, T., Li, F., Li, J., & Chen, F. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.761518 · Cited by 16 · cited 2×
“Its antifungal potential was confirmed in the in vivo study on mice [93].”
BackgroundJamiu, A. T., Albertyn, J., Sebolai, O. M., Gcilitshana, O. M. N., & Pohl, C. H. (2021) · Medical Mycology · doi:10.1093/mmy/myab055 · Cited by 14
Bresciani, F. R., Santi, L., Beys‐da‐Silva, W. O., Berger, M., Barcellos, V. D. A., Schripsema, J., von Poser, G. L., Guimarães, J. A., & Vainstein, M. H. (2020) · Archiv der Pharmazie · doi:10.1002/ardp.202000133 · Cited by 10 · cited 1×
“Aqueous seed extract from Allamanda polyantha could also interfere with Cryptococcus morphology by inhibiting capsule formation and decreasing cell size [58].”
BackgroundBavaro, D. F., Balena, F., Ronga, L., Signorile, F., Romanelli, F., Stolfa, S., Sparapano, E., Carlo, C. D., Mosca, A., Monno, L., et al. (2021) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2021.101206 · Cited by 10
Toxicidad hepática inducida por terbinafina
Manzano, M. D. L. Á. M., Gallego, Á. G., Clavijo, G. O., & Martı́n, J. M. S. (2018) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2018.05.022 · Cited by 7
TERBINAFINE INDUCED HEPATOTOXICITY
Jha, R., Gross, S., Ahmad, H., & Dicker, M. (2004) · The American Journal of Gastroenterology · doi:10.14309/00000434-200410001-00517 · Cited by 3
Jura, S., & Hillenbrand, K. M. (2006) · Pediatrics in Review · doi:10.1542/pir.27.4.158 · Cited by 3
Jura, S., & Hillenbrand, K. M. (2006) · Pediatrics in Review · doi:10.1542/pir.27-4-158 · Cited by 2
Cited by
Yassin, M. T., Mostafa, A. A.-F., Al-Askar, A. A., & Al-Otibi, F. O. (2022) · Crystals · doi:10.3390/cryst12060774 · Cited by 96
Recent Advances in the Allergic Cross-Reactivity between Fungi and Foods
Xing, H., Wang, J., Sun, Y., & Wang, H. (2022) · Journal of Immunology Research · doi:10.1155/2022/7583400 · Cited by 92
Zhang, C.-W., Zhong, X., Zhao, Y.-S., Rajoka, M. S. R., Hashmi, M. H., Zhai, P. C., & Song, X. (2023) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2023.100262 · Cited by 72
Fish Skin Mucus Extracts: An Underexplored Source of Antimicrobial Agents
Díaz‐Puertas, R., Adamek, M., Mallavia, R. M., & Falcó, A. (2023) · Marine Drugs · doi:10.3390/md21060350 · Cited by 59
“This situation is substantially worsened by the long-lasting drought (with a few recent exceptions [4]) in the discovery of new classes of antibiotics since 1962 [1,5] and the continued scarcity and specificity of antifungals [6] and antivirals [7].”
BackgroundInfluentialRecent drug development and treatments for fungal infections
Roy, M., Karhana, S., Shamsuzzaman, M., & Khan, M. A. (2023) · Brazilian Journal of Microbiology · doi:10.1007/s42770-023-00999-z · Cited by 51
“Terbinafine, when applied topically, causes adverse events like gastrointestinal disturbance, erythema, urticaria, rashes, neutropenia, and musculoskeletal reactions [46].”
Background
Metadata
- Authors
- Ivanov, M., Ćirić, A., & Stojković, D.
- Affiliations
- University of Belgrade (RS)
- Corresponding author
- Ivanov, Marija
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-03-02
- Volume
- 23
- Issue
- 5
- Pages
- 2756
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8911111
- OpenAlex
- W4214877855
- Cited by
- 160
- References
- 154
- Citations by year
- 2026: 31 · 2025: 46 · 2024: 36 · 2023: 35 · 2022: 12
- FWCI
- 4.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministarstvo prosvete, nauke i tehnoloskog razvoja (451-03-9/2021–14/200007)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
- Keywords
- antifungal drug discovery, antifungal drug targets, fungal infection, efflux pumps, HSP90, fungal virulence factors, biofilm, fungal hyphae, fungal enzymes, fungal metabolism, mitochondria, cell wall, antifungal vaccines, plant extracts, natural products, synthetic compounds, drug resistance
- MeSH terms
- Antifungal Agents, Cell Wall, Humans, Mycoses, Biofilms, Drug Resistance, Fungal, Hyphae
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.